A 52-year-old man with a 15-year history of poorly controlled hypertension presents to the cardiology clinic. Echocardiography shows concentric left ventricular hypertrophy with normal chamber dimensions and preserved ejection fraction. His blood pressure is 160/100 mmHg despite being on amlodipine 5 mg daily. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient demonstrates **concentric left ventricular hypertrophy (LVH)** — a classic adaptive response of cardiac myocytes to chronic pressure overload from hypertension. The hypertrophied myocardium increases wall thickness to normalize wall stress (LaPlace's law), but this adaptation eventually becomes maladaptive if the underlying stimulus (uncontrolled hypertension) persists. ## Pathophysiology of LVH in Hypertension **Key Point:** Concentric LVH represents myocyte hypertrophy (increase in individual cell size) without chamber dilation. This is a compensatory adaptation, but if hypertension remains uncontrolled, it progresses to diastolic dysfunction, fibrosis, and eventual systolic failure. ## Management Strategy The cornerstone of managing LVH secondary to hypertension is **aggressive blood pressure control**. Current guidelines recommend: 1. **Intensify antihypertensive therapy** — the patient is on monotherapy (amlodipine 5 mg) with inadequate BP control (160/100 mmHg). 2. **ACE inhibitors or ARBs are preferred** — these agents not only lower BP but also promote **regression of LVH** through reduction of angiotensin II–mediated fibrosis and myocyte growth. This is a unique cardioprotective benefit beyond BP reduction. 3. Target BP: <130/80 mmHg per current guidelines. **High-Yield:** ACE-I/ARB are superior to other antihypertensives for LVH regression because they block RAAS-mediated hypertrophy and fibrosis, not just reduce BP. ## Why This Is "Next Step" The patient has: - Preserved ejection fraction (no systolic dysfunction yet) - No evidence of acute decompensation - Suboptimal medical therapy (monotherapy on low-dose amlodipine) The immediate priority is **optimizing medical management** to halt progression and promote LVH regression, not investigation or device therapy. ## Clinical Pearl LVH is a **reversible adaptive response** if the hypertensive stimulus is removed or controlled early. Regression of LVH with antihypertensive therapy (especially ACE-I/ARB) is associated with improved outcomes and reduced arrhythmia risk.